Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

3.850 +0.010 (+0.26%)
Delayed Quote Updated: 1:24 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 299,873
Open 3.850
Bid (Size) 3.850 (500)
Ask (Size) 3.860 (200)
Prev. Close 3.840
Today's Range 3.790 - 3.910
52wk Range 3.595 - 50.40
Shares Outstanding 58,102,949
Dividend Yield 374.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-75.9%
-75.9%
1 Month
-26.1%
-26.1%
3 Month
-33.5%
-33.5%
6 Month
-58.8%
-58.8%
1 Year
-91.7%
-91.7%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗
Via Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
LENZ Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
Via The Motley Fool
News headline image
Why Lenz Therapeutics Stock Crashed Today ↗
Via The Motley Fool
News headline image
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
Via Benzinga

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
What is the current price of LENZ Therapeutics, Inc. - Common Stock?
The current price of LENZ Therapeutics, Inc. - Common Stock is 3.850
When was LENZ Therapeutics, Inc. - Common Stock last traded?
The last trade of LENZ Therapeutics, Inc. - Common Stock was at 10/01/26 01:24 PM ET
What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 223.70M
How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
LENZ Therapeutics, Inc. - Common Stock has 224M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.